Novo Nordisk AS (CHIX:NOVOBC) Cyclically Adjusted Revenue per Share: kr0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:NOVOBC Novo Nordisk AS CHIX:NOVOBC
80 GF Score
Price kr306.23
GF Value kr711.43
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Novo Nordisk AS Cyclically Adjusted Revenue per Share?

Novo Nordisk AS CHIX:NOVOBC +1.49% 80 Cyclically Adjusted Revenue per Share is kr0.00 as of Jun. 2026. GuruFocus rates CHIX:NOVOBC with a GF Score™ of 80/100 and a GF Value™ of kr711.43 (Significantly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Novo Nordisk AS's adjusted revenue per share for the three months ended in Jun. 2026 was kr17.694. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is kr0.00 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Novo Nordisk AS's average Cyclically Adjusted Revenue Growth Rate was 14.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 14.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 15.10% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 12.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Novo Nordisk AS was 16.10% per year. The lowest was 6.30% per year. And the median was 12.40% per year.

As of today (2026-08-08), Novo Nordisk AS's current stock price is kr306.225. Novo Nordisk AS's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was kr0.00. Novo Nordisk AS's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Novo Nordisk AS was 31.25. The lowest was 5.56. And the median was 10.88.


Novo Nordisk AS  (CHIX:NOVOBc) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Novo Nordisk AS was 31.25. The lowest was 5.56. And the median was 10.88.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Novo Nordisk AS Cyclically Adjusted Revenue per Share Related Terms


Novo Nordisk AS Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Novo Nordisk AS's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novo Nordisk AS Cyclically Adjusted Revenue per Share Chart

Novo Nordisk AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.89 27.37 30.67 36.40 41.00

Novo Nordisk AS Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.81 40.44 41.00 43.12 0.00

CHIX:NOVOBC vs LLY, JNJ, ABBV: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, Novo Nordisk AS's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novo Nordisk AS Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Novo Nordisk AS's Cyclically Adjusted PS Ratio falls into.


CHIX:NOVOBC
80GF Score
Novo Nordisk AS CHIX:NOVOBC
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novo Nordisk AS Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Novo Nordisk AS's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=17.694/122.9700*122.9700
=17.694

Current CPI (Jun. 2026) = 122.9700.

Novo Nordisk AS Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 5.440 100.200 6.676
201612 5.878 100.300 7.207
201703 5.690 101.200 6.914
201706 5.830 101.200 7.084
201709 5.389 101.800 6.510
201712 5.685 101.300 6.901
201803 5.513 101.700 6.666
201806 5.637 102.300 6.776
201809 5.738 102.400 6.891
201812 6.181 102.100 7.444
201903 6.127 102.900 7.322
201906 6.301 102.900 7.530
201909 6.379 102.900 7.623
201912 6.858 102.900 8.196
202003 7.193 103.300 8.563
202006 6.398 103.200 7.624
202009 6.622 103.500 7.868
202012 6.911 103.400 8.219
202103 7.299 104.300 8.606
202106 7.163 105.000 8.389
202109 7.753 105.800 9.011
202112 8.358 106.600 9.641
202203 9.204 109.900 10.299
202206 9.065 113.600 9.813
202209 10.043 116.400 10.610
202212 10.634 115.900 11.283
202303 11.825 117.300 12.397
202306 12.060 116.400 12.741
202309 13.083 117.400 13.704
202312 14.722 116.700 15.513
202403 14.618 118.400 15.182
202406 15.241 118.500 15.816
202409 15.987 118.900 16.534
202412 19.231 118.900 19.889
202503 17.562 120.200 17.967
202506 17.284 120.700 17.609
202509 16.861 121.600 17.051
202512 17.788 121.200 18.048
202603 21.764 121.680 21.995
202606 17.694 122.970 17.694

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of kr0.00 mean?
Novo Nordisk AS (CHIX:NOVOBC) has a Cyclically Adjusted Revenue per Share of kr0.00 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Novo Nordisk AS and its competitors.
Is Novo Nordisk AS's Cyclically Adjusted Revenue per Share too high?
Novo Nordisk AS's current Cyclically Adjusted Revenue per Share is kr0.00. Overall, Novo Nordisk AS has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novo Nordisk AS's Cyclically Adjusted Revenue per Share compare to LLY and JNJ?
Novo Nordisk AS's Cyclically Adjusted Revenue per Share of kr0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Novo Nordisk AS and its competitors. Novo Nordisk AS's current Cyclically Adjusted Revenue per Share is kr0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novo Nordisk AS stock overvalued right now?
Based on GuruFocus' analysis, Novo Nordisk AS (CHIX:NOVOBC) is currently considered Significantly Undervalued. The stock's GF Value™ is kr711.43, compared to a current price of kr306.23 — trading 57% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is kr0.00. Novo Nordisk AS's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Novo Nordisk AS (CHIX:NOVOBC), the current Cyclically Adjusted Revenue per Share is kr0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novo Nordisk AS (CHIX:NOVOBC) Overvalued in 2026?

Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued. The current stock price of kr306.23 is trading 57% below its estimated GF Value™ of kr711.43. GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.

Key valuation signals for CHIX:NOVOBC:

  • Cyclically Adjusted Revenue per Share: kr0.00
  • GF Value™: kr711.43 vs. price of kr306.23 (57% below fair value)
  • GF Score™: 80/100 with 4 warning signs

No single metric tells the full story. See the CHIX:NOVOBC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Novo Nordisk AS Business Description

Address Novo Alle 1, Bagsvaerd, DNK, 2880
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
80GF Score

Get the complete analysis for CHIX:NOVOBC

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr306.23
Price
kr711.43
GF Value